An Effective CTL Peptide Vaccine for Ebola Zaire Based on Survivors’ CD8+ Targeting of a Particular Nucleocapsid Protein Epitope with Potential Implications for COVID-19 Vaccine Design

CV Herst; S Burkholz; J Sidney; A Sette; PE Harris; S Massey; T Brasel; E Cunha-Neto; DS Rosa; WCH Chao; R Carback; T Hodge; L Wang; S Ciotlos; P Lloyd; R Rubsamen

PBS buffer mock-vaccinated mice showed mortality increasing from the 100 PFU to 1,000 PFU as shown in Figure 4a and Figure 3a . We saw a paradoxical effect in control animals with survival increasing between 1,000PFU (Figure 3a) and 10,000 PFU ( Figure 5a ). We believe this was caused by innate immunity triggered by the very large maEBOV challenge. All mice in all vaccinated We saw what appears to be an innate immune response at the 10,000 PFU EBOV exposure level. It has been suggested that EBOV can mediate an innate immunity response through stimulation of TLR-4 [33] . Because the adjuvanted 7 author/funder. All rights reserved. No reuse allowed without permission.